2163-8306/asset/cover.gif?v=1&s=5a8e2b67cb0ca8aadca70d78ccac53d6c59eba47)
|
|
- Exposure–response analysis of adverse events associated with molibresib
and its active metabolites in patients with solid tumors
Authors:
Anu Shilpa Krishnatry; Eva Hanze,
Tim Bergsma,
Arindam Dhar,
Marita Prohn,
Geraldine Ferron‐Brady
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 556-568, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12724
Issue No: Vol. 11, No. 5 (2022)
- Proarrhythmic risk assessment of drugs by dVm/dt shapes using the
convolutional neural network
Authors:
Da Un Jeong; Yedam Yoo,
Aroli Marcellinus,
Ki‐Suk Kim,
Ki Moo Lim
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 653-664, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12803
Issue No: Vol. 11, No. 5 (2022)
- A novel cardiovascular systems model to quantify drugs effects on the
inter‐relationship between contractility and other hemodynamic variables
Authors:
Yu Fu; Hadi Taghvafard,
Medhat M. Said,
Eric I. Rossman,
Teresa A. Collins,
Stéphanie Billiald‐Desquand,
Derek Leishman,
Piet H. Graaf,
J. G. Coen Hasselt,
Nelleke Snelder
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 640-652, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12774
Issue No: Vol. 11, No. 5 (2022)
- Using thrombocytopenia modeling to investigate the mechanisms underlying
platelet depletion induced by pan‐proteasome inhibitors
Authors:
Floriane Lignet; Andreas D. Becker,
Claude Gimmi,
Felix Rohdich,
Samer El Bawab
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 594-603, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12743
Issue No: Vol. 11, No. 5 (2022)
- A semimechanistic population pharmacokinetic and pharmacodynamic model
incorporating autoinduction for the dose justification of TAS‐114
Authors:
Hikari Araki; Toru Takenaka,
Koichi Takahashi,
Fumiaki Yamashita,
Kazuaki Matsuoka,
Kunihiro Yoshisue,
Ichiro Ieiri
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 604-615, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12747
Issue No: Vol. 11, No. 5 (2022)
- A modeling‐based proposal for safe and efficacious reintroduction of
Authors:
Lina Keutzer; Yasamin Akhondipour Salehabad,
Lina Davies Forsman,
Ulrika S. H. Simonsson
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 628-639, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12768
Issue No: Vol. 11, No. 5 (2022)
- Quantitative systems pharmacology model‐based investigation of adverse
gastrointestinal events associated with prolonged treatment with
PI3‐kinase inhibitors
Authors:
Kapil Gadkar; Christina Friedrich,
Vincent Hurez,
Maria‐Luisa Ruiz,
Leslie Dickmann,
Mohit Kumar Jolly,
Leah Schutt,
Jin Jin,
Joseph A. Ware,
Saroja Ramanujan
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 616-627, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12749
Issue No: Vol. 11, No. 5 (2022)
- Erdafitinib’s effect on serum phosphate justifies its
pharmacodynamically guided dosing in patients with cancer
Authors:
Anne‐Gaëlle Dosne; Elodie Valade,
Kim Stuyckens,
Peter De Porre,
Anjali Avadhani,
Anne O’Hagan,
Lilian Y. Li,
Daniele Ouellet,
Ruben Faelens,
Quentin Leirens,
Italo Poggesi,
Juan Jose Perez Ruixo
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 569-580, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12727
Issue No: Vol. 11, No. 5 (2022)
- Semimechanistic models to relate noxious stimulation, movement, and
pupillary dilation responses in the presence of opioids
Authors:
Nicolás Marco‐Ariño; Sergio Vide,
Mercè Agustí,
Andrew Chen,
Sebastián Jaramillo,
Itziar Irurzun‐Arana,
Adrià Pacheco,
Carmen Gonzalez,
Erik W. Jensen,
Patricia Capsi‐Morales,
José F. Valencia,
Iñaki F. Troconiz,
Pedro L. Gambus,
Merlin D. Larson
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 581-593, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12729
Issue No: Vol. 11, No. 5 (2022)
- Challenges faced when modeling clinical toxicology and toxinology events
Authors:
Stephen Duffull; Geoff Isbister
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 532-534, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12792
Issue No: Vol. 11, No. 5 (2022)
- Addressing drug safety of maternal therapy during breastfeeding using
physiologically‐based pharmacokinetic modeling
Authors:
Xian Pan; Karen Rowland Yeo
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 535-539, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12802
Issue No: Vol. 11, No. 5 (2022)
- Quantitative approaches to drug safety: The 2022 PSP special issue
Authors:
Eric A. Sobie
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 529-531, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12804
Issue No: Vol. 11, No. 5 (2022)
- Issue Information
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 525-528, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12652
Issue No: Vol. 11, No. 5 (2022)
- Advancing drug safety science by integrating molecular knowledge with
post‐marketing adverse event reports
Authors:
Theodoros G. Soldatos; Sarah Kim,
Stephan Schmidt,
Lawrence J. Lesko,
David B. Jackson
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 540-555, May 2022.
PubDate: 2022-05-22T12:00:00-07:00
DOI: 10.1002/psp4.12765
Issue No: Vol. 11, No. 5 (2022)
- Multi‐phase Multi‐Layer Mechanistic Dermal Absorption (MPML MechDermA)
Model to predict local and systemic exposure of drug products applied on
skin
Authors:
Nikunjkumar Patel; James F. Clarke,
Farzaneh Salem,
Tariq Abdulla,
Frederico Martins,
Sumit Arora,
Eleftheria Tsakalozou,
Arran Hodgkinson,
Omid Arjmandi‐Tash,
Sinziana Cristea,
Priyanka Ghosh,
Khondoker Alam,
Sam G. Raney,
Masoud Jamei,
Sebastian Polak
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article.
PubDate: 2022-06-07T02:06:34-07:00
DOI: 10.1002/psp4.12814
- Tutorial: Evaluation of Covariate Effects using Forest Plots and
Introduction to the coveffectsplot R package
Authors:
J. F. Marier; Nathan Teuscher,
Mohamad‐Samer Mouksassi
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article.
PubDate: 2022-06-07T02:06:28-07:00
DOI: 10.1002/psp4.12829
- Robust physiologically based pharmacokinetic model of rifampicin for
predicting drug–drug interactions via P‐glycoprotein induction and
inhibition in the intestine, liver, and kidney
Authors:
Ryuta Asaumi; Ken‐ichi Nunoya,
Yoshiyuki Yamaura,
Kunal S. Taskar,
Yuichi Sugiyama
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-06-06T05:45:02-07:00
DOI: 10.1002/psp4.12807
- Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in
Authors:
Stefan Willmann; Ibrahim Ince,
Maurice Ahsman,
Katrin Coboeken,
Yang Zhang,
Kirstin Thelen,
Dagmar Kubitza,
Peter Zannikos,
Wangda Zhou,
Liza Miriam Pina,
Teun Post,
Jörg Lippert
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article.
PubDate: 2022-06-05T11:24:34-07:00
DOI: 10.1002/psp4.12830
- The area under the effect curve as an efficacy determinant for
anti‐infectives
Authors:
Chao Chen; Silvia Maria Lavezzi,
Laura Iavarone
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-31T01:39:10-07:00
DOI: 10.1002/psp4.12811
- Deep compartment models: A deep learning approach for the reliable
prediction of time‐series data in pharmacokinetic modeling
Authors:
Alexander Janssen; Frank W. G. Leebeek,
Marjon H. Cnossen,
Ron A. A. Mathôt,
for the OPTI‐CLOT study group SYMPHONY consortium,
K. Fijnvandraat,
M. Coppens,
K. Meijer,
S. E. M. Schols,
H. C. J. Eikenboom,
R. E. G. Schutgens,
E. A. M. Beckers,
P. Ypma,
M. J. H. A. Kruip,
S. Polinder,
R. Y. J. Tamminga,
P. Brons,
K. Fischer,
K. P. M. Galen,
L. Nieuwenhuizen,
M. H. E. Driessens,
I. Vliet,
J. Lock,
H. C. A. M. Hazendonk,
I. Moort,
J. M. Heijdra,
M. H. J. Goedhart,
W. Al Arashi,
T. Preijers,
N. C. B. Jager,
L. H. Bukkems,
M. E. Cloesmeijer,
P. W. Collins,
R. Liesner,
P. Chowdary,
C. M. Millar,
D. Hart,
D. Keeling
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-27T02:40:01-07:00
DOI: 10.1002/psp4.12808
- Population Pharmacokinetic Model for Once Daily Intravenous Busulfan in
Paediatric Subjects Describing Time‐Associated Clearance
Authors:
Rachael Lawson; Christine E. Staatz,
Christopher J. Fraser,
Shanti Ramachandran,
Lochie Teague,
Richard Mitchell,
Tracey O’Brien,
Stefanie Hennig
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article.
PubDate: 2022-05-25T05:13:36-07:00
DOI: 10.1002/psp4.12809
- Quantitative system pharmacology as a legitimate approach to examine
extrapolation strategies used to support pediatric drug development
Authors:
Karim Azer; Jeffrey S. Barrett
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-24T02:51:21-07:00
DOI: 10.1002/psp4.12801
- Evaluation of drug–drug interaction potential for pemigatinib using
physiologically based pharmacokinetic modeling
Authors:
Tao Ji; Xuejun Chen,
Swamy Yeleswaram
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-23T09:28:02-07:00
DOI: 10.1002/psp4.12805
- Machine learning algorithms to estimate everolimus exposure trained on
simulated and patient pharmacokinetic profiles
Authors:
Marc Labriffe; Jean‐Baptiste Woillard,
Jean Debord,
Pierre Marquet
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-22T10:23:54-07:00
DOI: 10.1002/psp4.12810
- Population Pharmacokinetic/Pharmacodynamic Joint Modeling of Ixazomib
Efficacy and Safety Using Data from the Pivotal Phase 3 TOURMALINE‐MM1
Study in Multiple Myeloma Patients
Authors:
Jaydeep K. Srimani; Paul M. Diderichsen,
Michael J. Hanley,
Karthik Venkatakrishnan,
Richard Labotka,
Neeraj Gupta
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article.
PubDate: 2022-05-22T04:28:23-07:00
DOI: 10.1002/psp4.12815
- Modeling the bacterial dynamics in the gut microbiota following an
antibiotic‐induced perturbation
Authors:
Jinju Guk; Antoine Bridier‐Nahmias,
Mélanie Magnan,
Nathalie Grall,
Xavier Duval,
Olivier Clermont,
Etienne Ruppé,
Camille d'Humières,
Olivier Tenaillon,
Erick Denamur,
France Mentré,
Jérémie Guedj,
Charles Burdet,
for the CEREMI study group
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-18T04:41:10-07:00
DOI: 10.1002/psp4.12806
- Introduction of an artificial neural network–based method for
concentration‐time predictions
Authors:
Dominic Stefan Bräm; Neil Parrott,
Lucy Hutchinson,
Bernhard Steiert
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-18T01:50:14-07:00
DOI: 10.1002/psp4.12786
- Flexible and efficient Bayesian pharmacometrics modeling using Stan and
Torsten, Part I
Authors:
Charles C. Margossian; Yi Zhang,
William R. Gillespie
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article.
PubDate: 2022-05-15T08:49:35-07:00
DOI: 10.1002/psp4.12812
- Population pharmacokinetics for oral paclitaxel in patients with
advanced/metastatic solid tumors
Authors:
Jimmy He; Christopher G. C. A. Jackson,
Sanjeev Deva,
Tak Hung,
Katriona Clarke,
Eva Segelov,
Tsu‐Yi Chao,
Ming‐Shen Dai,
Hsien‐Tang Yeh,
Wen Wee Ma,
Douglas Kramer,
Wing‐Kai Chan,
Rudolf Kwan,
David Cutler,
Jay Zhi
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-10T09:44:06-07:00
DOI: 10.1002/psp4.12799
- Predicting disease activity in patients with multiple sclerosis: An
explainable machine‐learning approach in the Mavenclad trials
Authors:
Sreetama Basu; Alain Munafo,
Ali‐Frederic Ben‐Amor,
Sanjeev Roy,
Pascal Girard,
Nadia Terranova
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-09T12:33:58-07:00
DOI: 10.1002/psp4.12796
- Quantitative systems pharmacology modeling provides insight into
inter‐mouse variability of Anti‐CTLA4 response
Authors:
Wenlian Qiao; Lin Lin,
Carissa Young,
Jatin Narula,
Fei Hua,
Andrew Matteson,
Andrea Hooper,
Lore Gruenbaum,
Alison Betts
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-08T10:25:12-07:00
DOI: 10.1002/psp4.12800
- Development and application of a pediatric mechanistic kidney model
Authors:
Farzaneh Salem; Ben G. Small,
Trevor N. Johnson
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-04T01:34:49-07:00
DOI: 10.1002/psp4.12798
- Use of physiologically‐based pharmacokinetic modeling to inform dosing
of the opioid analgesics fentanyl and methadone in children with obesity
Authors:
Jacqueline G. Gerhart; Fernando O. Carreño,
Jennifer L. Ford,
Andrea N. Edginton,
Eliana M. Perrin,
Kevin M. Watt,
William J. Muller,
Andrew M. Atz,
Amira Al‐Uzri,
Paula Delmore,
Daniel Gonzalez, on behalf of the
Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee,
Daniel K. Benjamin,
Christoph Hornik,
Kanecia Zimmerman,
Phyllis Kennel,
Rose Beci,
Chi Dang Hornik,
Gregory L. Kearns,
Matthew Laughon,
Ian M. Paul,
Janice Sullivan,
Kelly Wade,
Paula Delmore,
Perdita Taylor‐Zapata,
June Lee,
Ravinder Anand,
Gaurav Sharma,
Gina Simone,
Kim Kaneshige,
Lawrence Taylor,
Amira Al‐Uzri,
Chi Hornik,
Gregory Sokol,
David Speicher,
Janice Sullivan,
Peter Mourani,
Susan Mendley,
Marisa Meyer,
Robert Atkins,
Joseph Flynn,
Janelle Vaughns,
Catherine Sherwin,
Paula Delmore,
Stuart Goldstein,
Mobeen Rathore,
Chiara Melloni,
William Muller,
Paula Delmore,
Adriana Tremoulet,
Laura James,
Susan Mendley,
Martha Blackford,
Andrew Atz,
Michelle Adu‐Darko,
Peter Mourani,
Kevin Watt,
Chi Hornik,
Amira Al‐Uzri,
Janice Sullivan,
Matthew Laughon,
P. Brian Smith,
Kevin Watt,
Ira Cheifetz,
Andrew Atz,
Varsha Bhatt‐Mehta,
Allison Fernandez,
Jennifer Lowry
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-05-02T01:30:17-07:00
DOI: 10.1002/psp4.12793
- Finding the right hazard function for time‐to‐event modeling: A
tutorial and Shiny application
Authors:
Rob C. Wijk; Ulrika S. H. Simonsson
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-28T10:48:53-07:00
DOI: 10.1002/psp4.12797
- Prediction of CYP‐mediated DDIs involving inhibition: Approaches to
Authors:
Peter J. Kilford; Kuan‐Fu Chen,
Kim Crewe,
Iain Gardner,
Oliver Hatley,
Alice Ban Ke,
Sibylle Neuhoff,
Mian Zhang,
Karen Rowland Yeo
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-28T01:14:21-07:00
DOI: 10.1002/psp4.12794
- Population PBPK modeling using parametric and nonparametric methods of the
Simcyp Simulator, and Bayesian samplers
Authors:
Janak R. Wedagedera; Anthonia Afuape,
Siri Kalyan Chirumamilla,
Hiroshi Momiji,
Robert Leary,
Mike Dunlavey,
Richard Matthews,
Khaled Abduljalil,
Masoud Jamei,
Frederic Y. Bois
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-22T04:55:41-07:00
DOI: 10.1002/psp4.12787
- Model‐informed drug development of voxelotor in sickle cell disease:
Exposure‐response analysis to support dosing and confirm mechanism of
action
Authors:
Michelle L. Green; Radojka M. Savic,
Margaret Tonda,
Karin Jorga,
Carla B. Washington
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-21T12:33:33-07:00
DOI: 10.1002/psp4.12780
- Model‐informed drug development of voxelotor in sickle cell disease:
Population pharmacokinetics in whole blood and plasma
Authors:
Radojka M. Savic; Michelle L. Green,
Karin Jorga,
Michael Zager,
Carla B. Washington
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-21T12:30:03-07:00
DOI: 10.1002/psp4.12731
- Quantitative methods and modeling to assess COVID‐19‐interrupted in
vivo pharmacokinetic bioequivalence studies with two reference batches
Authors:
Yuqing Gong; Kairui Feng,
Peijue Zhang,
Jieon Lee,
Yuzhuo Pan,
Zhen Zhang,
Zhanglin Ni,
Tao Bai,
Miyoung Yoon,
Bing Li,
Carol Y. Kim,
Lanyan Fang,
Liang Zhao
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-20T04:29:02-07:00
DOI: 10.1002/psp4.12795
- Guide to development of compound files for PBPK modeling in the Simcyp
population‐based simulator
Authors:
Udoamaka Ezuruike; Mian Zhang,
Amita Pansari,
Mailys De Sousa Mendes,
Xian Pan,
Sibylle Neuhoff,
Iain Gardner
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-18T09:54:31-07:00
DOI: 10.1002/psp4.12791
- A quantitative approach to the choice of number of samples for percentile
estimation in bootstrap and visual predictive check analyses
Authors:
E. Niclas Jonsson; Joakim Nyberg
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-17T11:54:59-07:00
DOI: 10.1002/psp4.12790
- Exposure‐response analyses for selection/confirmation of optimal
isatuximab dosing regimen in combination with pomalidomide/dexamethasone
treatment in patients with multiple myeloma
Authors:
Fatiha Rachedi; Kimiko Koiwai,
Nadia Gaudel‐Dedieu,
Bernard Sebastien,
Hoai‐Thu Thai,
Claire Brillac,
Jean Baptiste Fau,
Laurent Nguyen,
Helgi van de Velde,
Christine Veyrat‐Follet,
Dorothée Semiond
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-17T11:29:06-07:00
DOI: 10.1002/psp4.12789
- Population pharmacokinetics of mobocertinib in healthy volunteers and
patients with non–small cell lung cancer
Authors:
Neeraj Gupta; Philippe B. Pierrillas,
Michael J. Hanley,
Steven Zhang,
Paul M. Diderichsen
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-11T11:24:05-07:00
DOI: 10.1002/psp4.12785
- Perspectives on training quantitative systems pharmacologists
Authors:
Tongli Zhang; Carolyn R. Cho,
Peter L. Bonate
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-07T01:09:01-07:00
DOI: 10.1002/psp4.12783
- Optimized sampling to estimate vancomycin drug exposure: Comparison of
pharmacometric and equation‐based approaches in a
simulation‐estimation study
Authors:
David W. Uster; Sebastian G. Wicha
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-05T10:49:09-07:00
DOI: 10.1002/psp4.12782
- PK/PD modeling links accelerated resolution of COVID‐19‐related
clinical symptoms to SARS‐CoV‐2 viral load reduction in patients
following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab
together
Authors:
C. Steven Ernest; Jenny Y. Chien,
Dipak R. Patel,
Emmanuel Chigutsa
Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView.
PubDate: 2022-04-05T10:12:45-07:00
DOI: 10.1002/psp4.12784
|
Open Access journal
